Advice
in the absence of a submission from the holder of the marketing authorisation
atezolizumab (Tecentriq®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice236KB (PDF)
Medicine details
- Medicine name:
- atezolizumab (Tecentriq)
- SMC ID:
- SMC2769
- Indication:
As monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Date advice published
- 10 March 2025